The real-time, non-invasive, in-vivo skin cancer detection device, Spectra-Scope®, incorporates a real-time assessment feature and eliminates waiting time for patients. Since the diagnostics can be performed right in the dermatologists’ clinic, the process can be completed in a matter of few minutes. What makes the product shine in the market is its capability to generate reports by just analyzing the chemical composition of the skin cells rather than using subjective visual based assessment, resulting in high detection accuracy and non-biased outcome by examiner’s skill level. Spectra-Scope® uses commercially available aesthetic laser, which is widely commercialized for various skin treatments, safely to diagnose the skin disease.
Catering to a wide range of skin clinics who currently conduct skin check-up or/and skin biopsy, typically operated by dermatologist, general practitioners, physician assistants, nurse practitioners, Speclipse has innovated two models— add-on Spectra-Scope® and stand-alone Spectra-Scope®.
To further mitigate the medical errors due to subjective interpretation, Speclipse’s machine learning-powered device has been designed by taking more than 6000 spectral data of skin lesions. By leveraging machine learning to train neural networks, Speclipse makes the device much more accurate compared to manually-driven diagnostic methods. This also makes the Spectra-Scope®’s accuracy practically indifferent with the skin cancer biopsy with higher than 90 percent accuracy while requiring no biopsy sample actually taken and no waiting of several days for the biopsy result.
Spectra-Scope® will be simply a game changer for skin cancer diagnosis at an office setting
“Even though our technology provides higher accuracy in contrast with the pathological skin biopsy, we rather position our technology as a complement to the biopsy initially by reducing disgnostic procedure time, making data less subjective and improving detection accuracy over visual methods at the office setting,” says Sungwoo Min, COO, Speclipse. “ThroughW fast screening with Spectra-Scope® any user regardless experience level can quickly pick one or two biopsy samples to achieve better medical outcome. Spectra- ScopeW will be simply a game changer for skin cancer diagnosis at an office setting with the comparable accuracy to the current gold standard, the skin cancer biopsy.”
So far, Speclipse has received approval for 12 patents and is now targeting for CE marking and TGA approvals, which indicate conformity with health and environmental protection. Extending the global footprint, the firm soon plans to penetrate in the European and Australian market. Climbing the ladder of success, Speclipse is also focused on expanding the scope of AI-enabled laser-induced spectroscopy to other types of cancers and other diagnostic applications as well.